Loading
Obesity / Quercetin / Diabetes · Phase 2 Trial
ClinicalTrials.gov · August 7, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed Phase 2 trial registered at ClinicalTrials.gov investigating whether quercetin affects glucose absorption in participants with obesity or obesity and type 2 diabetes, measured by oral glucose tolerance testing. No results are posted in this registry record, so efficacy, safety, or any clinical benefit cannot be assessed.
Phase 2, Interventional, Non Randomized, Crossover, Triple masking, Basic Science purpose. Obesity, Diabetes; age from 18 Years; to 65 Years. Intervention: 1 gram quercetin; 2 grams quercetin; placebo. Compared with: Placebo. n = 24. 1 site: United States.
This is a completed Phase 2 trial registered at ClinicalTrials.gov investigating whether quercetin affects glucose absorption in participants with obesity or obesity and type 2 diabetes, measured by oral glucose tolerance testing. No results are posted in this registry record, so efficacy, safety, or any clinical benefit cannot be assessed.
No effect sizes, p-values, or safety data are available to assess.
Until results are published, no clinical recommendation can be made. Clinicians and researchers should await peer-reviewed publication of outcomes before considering any change to obesity or diabetes management.
Phase 2 interventional study with small planned enrollment (24–32 participants) investigating a dietary compound on a surrogate measure; no results posted in registry record.
As stated by the source record.
Quoted from the source exactly as published.
Until results are published, no clinical recommendation can be made. Clinicians and researchers should await peer-reviewed publication of outcomes before considering any change to obesity or diabetes management.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT00065676). This is a study registration, not published results. Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 24 participants (ACTUAL). Conditions: Obesity, Diabetes. Interventions: OTHER: Quercetin; OTHER: Placebo. Primary outcome measures: Does quercetin effect glucose absorption , End of study. Brief summary: Quercetin is a compound naturally found in various foods. It may have some role in the treatment of obesity and diabetes. The purpose of this study is to investigate research volunteers with obesity or obesity with type 2 diabetes to determine whether quercetin affects the way glucose is absorbed by the body. Thirty two participants aged 19 to 65 who are considered to be medically obese or obese with type 2 diabetes will be enrolled in this study. Before the onset of treatment, they will undergo a medical history, physical exam, blood work, and urinalysis. During the study, participants will be given an oral glucose tolerance test three times; during these tests they will receive 1 or 2 grams of quercetin, or placebo. Researchers will collect blood samples and analyze the effect of the treatment on blood glucose. ...
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.